Zhe Xiao, Qu Qiu-min, Wang Rui-li, Cao Hong-mei, Qiao Jin, Guo Feng
Department of Neurology, the First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710061, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Oct;30(10):1065-8.
To investigate the treatment status of antiparkinsonism in Xi'an.
Six general hospitals were randomly chosen in Xi'an and all Parkinson's disease (PD) patients were interviewed by questionnaire from Jan. 2007 to Apr. 2007.
92 PD outpatients were enrolled in, including 48 males and 44 females, from 43 to 86 years old (mean 65.6 +/- 17.1) with duration of the disease from 0.2 to 27.8 years (mean 4.4 +/- 9.4). The preference of the drug use from the patients were: 40 (43.5%) preferred taking levodopa, 25 (27.2%) with amantadine and/or trihexyphenidyl, 14 (15.2%) with levodopa and others, 4 (4.4%) with dopamine agonist and others, 2 (2.2%) with other drugs, 7 (7.6%) with no treatment. There were 69 (75.0%) patients onset with resting tremor, 15 (16.3%) with bradykinesia, 6 (6.5%) with rigidity, and 2 (2.2%) with unknown symptoms. There was no startically significant difference in anti-PD drugs among the patients onset with different symptoms (P > 0.05). 45 patients appeared the onset of disease before 65 years old and with no dementia, 47 onset after 65 with or without dementia. There was no significant difference of anti-PD drugs between the two groups (P > 0.05). Most patients initiated anti-PD treatment with levodopa but few of them chose dopamine agonist. According to the classification of Hoehn & Yahr, 25(27.2%)belonged to Grade I, 53 (57.6%) to Grade II, 8 (8.7%) to Grade III, 3 (3.3%) to Grade IV and 3 (3.3%) to Grade V. There was no significant differences of anti-PD drugs between different grades of the disease (P > 0.05). 55.3% of the patients changed their anti-PD drugs randomly during the therapy, but with no relation to their gender, age, educational level, dementia, the number of family members, course of diseases, or the degree of Hoehn & Yahr, frequency and categories of medicine.
Anti-PD treatment in Xi'an did not strictly follow the standardized protocol, with few patients using dopamine agonist and over 50% of the patients changed their drugs randomly.
调查西安地区抗帕金森病的治疗现状。
于2007年1月至4月在西安随机选取6家综合医院，采用问卷调查的方式对所有帕金森病（PD）患者进行访谈。
共纳入92例PD门诊患者，其中男性48例，女性44例，年龄43至86岁（平均65.6±17.1岁），病程0.2至27.8年（平均4.4±9.4年）。患者用药偏好为：40例（43.5%）首选左旋多巴，25例（27.2%）选用金刚烷胺和/或苯海索，14例（15.2%）选用左旋多巴及其他药物，4例（4.4%）选用多巴胺激动剂及其他药物，2例（2.2%）选用其他药物，7例（7.6%）未接受治疗。69例（75.0%）患者以静止性震颤起病，15例（16.3%）以运动迟缓起病，6例（6.5%）以肌强直起病，2例（2.2%）起病症状不明。不同起病症状的患者在抗PD药物使用上无统计学显著差异（P>0.05）。45例患者在65岁前起病且无痴呆，47例在65岁后起病，有或无痴呆。两组患者的抗PD药物使用无显著差异（P>0.05）。多数患者以左旋多巴开始抗PD治疗，但很少有人选择多巴胺激动剂。根据Hoehn&Yahr分级，25例（27.2%）属于Ⅰ级，53例（57.6%）属于Ⅱ级，8例（8.7%）属于Ⅲ级，3例（3.3%）属于Ⅳ级，3例（3.3%）属于Ⅴ级。不同疾病分级的患者在抗PD药物使用上无显著差异（P>0.05）。55.3%的患者在治疗期间随意更换抗PD药物，但与性别、年龄、教育程度、痴呆情况、家庭成员数量、病程或Hoehn&Yahr分级、用药频率及种类无关。
西安地区的抗PD治疗未严格遵循标准化方案，使用多巴胺激动剂的患者较少，超过50%的患者随意换药。
Zotero 插件